Citation: Ds. Shepard, MANAGING MEDICINES - PUBLIC-POLICY AND THERAPEUTIC DRUGS - DAVIS,P, International journal for quality in health care, 10(2), 1998, pp. 169-169
Authors:
BEINECKE RH
SHEPARD DS
GOODMAN M
RIVERA M
Citation: Rh. Beinecke et al., ASSESSMENT OF THE MASSACHUSETTS MEDICAID MANAGED BEHAVIORAL HEALTH-PROGRAM - YEAR-3, Administration and policy in mental health, 24(3), 1997, pp. 205-220
Citation: Rh. Beinecke et al., THE MASSACHUSETTS MENTAL-HEALTH SUBSTANCE-ABUSE MANAGED CARE PROGRAM - THE PROVIDERS VIEW, Administration and policy in mental health, 23(5), 1996, pp. 379-391
Citation: Jj. Callahan et al., MENTAL-HEALTH SUBSTANCE-ABUSE TREATMENT IN MANAGED CARE - THE MASSACHUSETTS MEDICAID EXPERIENCE, Health affairs, 14(3), 1995, pp. 173-184
Authors:
SHEPARD DS
WALSH JA
KLEINAU E
STANSFIELD S
BHALOTRA S
Citation: Ds. Shepard et al., SETTING PRIORITIES FOR THE CHILDRENS VACCINE INITIATIVE - A COST-EFFECTIVENESS APPROACH, Vaccine, 13(8), 1995, pp. 707-714
Authors:
SHEPARD DS
STASON WB
PERRY HM
CARMEN BA
NAGURNEY JT
Citation: Ds. Shepard et al., MULTIVARIATE COST-EFFECTIVENESS ANALYSIS - AN APPLICATION TO OPTIMIZING AMBULATORY CARE FOR HYPERTENSION, Inquiry, 32(3), 1995, pp. 320-331
Citation: Ds. Shepard, ECONOMIC-ANALYSIS OF INVESTMENT PRIORITIES FOR MEASLES CONTROL, The Journal of infectious diseases, 170, 1994, pp. 190000056-190000062
Citation: Ds. Shepard, ECONOMIC-ANALYSIS OF INVESTMENT PRIORITIES FOR MEASLES CONTROL, The Journal of infectious diseases, 170, 1994, pp. 190000056-190000062